Search Results
Jul 23, 2026, 17:54 ET /C O R R E C T I O N -- MORE Foundation/
end: National MSK Leaders Convene in Scottsdale for Second Annual MSK Business Summit Focused on value-based care, ASC strategy, and innovation across musculoskeletal healthcarePHOENIX, July
More news about: MORE Foundation
Jul 23, 2026, 16:29 ET Charter Announces Debt Exchange Offers
Old Notes would result in the New Notes and such Old Notes being treated as "substantially different" under FASB Accounting Standards Codification ("ASC") 470-50 and (iii) that with respect to any Old Notes validly tendered pursuant to any Exchange Offer that will be exchanged on the Final Settlement
More news about: Charter Communications, Inc.
Jul 23, 2026, 12:00 ET Dr. Atul Kakkar Joins OCLI Vision in Floral Park, Massapequa and Woodbury
provides a comprehensive set of business support functions, including billing and collections, credential services, marketing, physician recruitment, ASC development, financial and accounting services, benefits and payroll management and information technology. The company's corporate service center is
More news about: OCLI Vision
Jul 23, 2026, 07:00 ET Harley-Davidson Delivers Second Quarter Financial Results and Raises Full-Year Guidance
represent the LiveWire reportable segment as determined in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 280 Segment Reporting which may differ from LiveWire Group, Inc. results.
More news about: Harley-Davidson, Inc.
Jul 22, 2026, 20:10 ET Ascletis Announces Oral Discussion of ASC36_35 FDC Preclinical Data Demonstrating Superior Weight Loss to Eloralintide/Tirzepatide Combination at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting
dual peptide agonist and ASC37, a GLP-1R/GIPR/GCGR triple peptide agonist, ASC39, an eloralintide-like potent and amylin-selective oral small molecule amylin receptor agonist, ASC30_39 FDC, a fixed-dose combination (FDC) of ASC30 (GLP-1 RA) and ASC39 (amylin RA), ASC30_48 FDC, a fixed-dose
More news about: Ascletis Pharma Inc.
Jul 22, 2026, 20:10 ET 歌禮宣佈將在第62屆歐洲糖尿病研究協會（EASD）年會上以口頭討論形式匯報ASC36_35 FDC減重效果優於eloralintide聯合tirzepatide的臨床前數據
摘要標題：ASC36與ASC35復方制劑，每月一次給藥的胰澱素受體激動劑和GLP-1R/GIPR雙靶點激動劑，在DIO大鼠中顯示出優於eloralintide聯合tirzepatide的減重效果（Co-formulation of ASC36 and ASC35, once-monthly amylin receptor agonist and GLP-1R/GIPR agonist, demonstrated superior weight loss to eloralintide/tirzepatide combo in DIO rats）
More news about: 歌禮製藥有限公司
Jul 22, 2026, 16:15 ET Ardmore Shipping Announces Second Quarter 2026 Conference Call and Webcast
HAMILTON, Bermuda, July 22, 2026 /PRNewswire/ -- Ardmore Shipping Corporation (NYSE: ASC) ("Ardmore" or the "Company") today announced that the Company plans to announce its second quarter earnings before the market opens on Wednesday, July
More news about: Ardmore Shipping Corporation
Jul 22, 2026, 10:30 ET AI in Drug Discovery Market worth $17.56 billion by 2031 - Exclusive Report by MarketsandMarkets™
(Imaging, Robotics, AI Scribe, Telehealth, CDS, Precision Medicine, Radiation, RCM, Cybersecurity), Tools (ML, NLP, Computer Vision), End User (Hospital, ASC, Payer) - Global Forecast to 2031
More news about: MarketsandMarkets
Jul 22, 2026, 10:04 ET Sony Electronics Launches the FX5, a Cinema Line Camera with a Newly Developed Image Sensor, Open Gate Recording, Internal RAW Recording, and Enhanced Operability
CAD.ILME-FX5B body will be available mid-August for a suggested retail price of $4,899.99 USD / $6,299.99 CAD.Claudio Miranda, ASC, cinematographer of films including "Top Gun: Maverick" and "F1® The Movie," conducted a test shoot with the FX5:"I felt that FX5 is a camera
More news about: Sony Electronics, Inc.
Jul 22, 2026, 10:00 ET Creality Pika Pocket-Sized AI 3D Scanner Is Now on Sale at $699
than conventional texture mapping --- useful for display, portfolio, and social sharing as well as archival capture. Scans export to STL, OBJ, PLY, and ASC for mainstream 3D printing and modeling pipelines, and CrealityScan continues to receive OTA updates.Price and AvailabilityCreality
More news about: CREALITY 3D
Jul 21, 2026, 17:30 ET Top 10 Medical Device Technologies Market worth $829.69 billion by 2031 - Exclusive Report by MarketsandMarkets™
Prosthetics, Spinal Implant, Brace, Orthobiologics (DBM), Bone Graft), Procedures Volume (Knee, Hip, Ankle, Shoulder) Site, Application, End User (Hospital, ASC, Trauma) - Global Forecast to 2030About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America's Best Management
More news about: MarketsandMarkets
Jul 21, 2026, 08:00 ET Cinctive Continues Expansion with New Office in West Palm Beach and Additions to Investment Team
https://www.cinctive.com/.Media ContactsSteve Bruce / Mary Beth GroverASC [email protected] /
More news about: Cinctive Capital Management
Jul 20, 2026, 10:01 ET Behavioral/Mental Health Software Market worth $8.43 billion by 2031 - Exclusive Report by MarketsandMarkets™
(Teleconsultation, RPM, Diagnostics & Treatment, Analytics, Administrative), Application (TelelCU, Teleradiology, Telecardiology, Diabetes), End User (Hospital, ASC, Payer), & Region - Global Forecast to 2030
More news about: MarketsandMarkets
Jul 16, 2026, 10:07 ET SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of July 20, 2026 in Veritone, Inc. Lawsuit - VERI
Company itself confirmed the restatement was necessary, citing errors in on-premise software valuation and agent-versus-principal misclassification under ASC 606.For institutional holders, these alleged misstatements are significant: the originally reported 32.4% year-over-year revenue
More news about: SueWallSt.com
Jul 16, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Veritone, Inc. of Class Action Lawsuit and Upcoming Deadlines - VERI
three and twelve months ended December 31, 2025 because it is currently finalizing its accounting determination of certain revenue transactions under ASC 606." On this news, Veritone's stock price fell $0.77 per share, or 29.5%, to close at $1.84 per share on March 27, 2026. Then, on April
More news about: Pomerantz LLP
Jul 15, 2026, 10:11 ET Levi & Korsinsky Reminds Veritone, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of July 20, 2026 - VERI
prospectus failed to disclose that Veritone had misclassified revenue and costs in transactions where it acted as an agent rather than a principal under ASC 606Accounts receivable incorporated into the offering documents were allegedly overstated by $0.9 millionThe Company's
More news about: Levi & Korsinsky, LLP
Jul 15, 2026, 10:00 ET Surgical Information Systems Names Rob Duffy Chief Technology Officer
what matters most: delivering exceptional patient care and outcomes.Recognized as the No. 1 ASC EHR vendor by Black Book for 11 consecutive years and honored with the Best in KLAS Award for ASC Solutions in 2026, 2025, 2023, and 2022, SIS remains the trusted choice for surgical providers seeking
More news about: SURGICAL INFORMATION SYSTEMS
Jul 15, 2026, 06:00 ET Ascletis Selects for Clinical Development a Fixed-Dose Combination of First-in-Class Oral Small Molecule GIPR Agonist, ASC48, and Oral Small Molecule GLP-1R Agonist, ASC30
dual peptide agonist and ASC37, a GLP-1R/GIPR/GCGR triple peptide agonist, ASC39, an eloralintide-like potent and amylin-selective oral small molecule amylin receptor agonist, ASC30_39 FDC, a fixed-dose combination (FDC) of ASC30 (GLP-1 RA) and ASC39 (amylin RA), ASC30_48 FDC, a fixed-dose
More news about: Ascletis Pharma Inc.
Jul 15, 2026, 06:00 ET 歌禮選定同類首創口服小分子GIPR激動劑ASC48和口服小分子GLP-1R激動劑ASC30的固定劑量復方制劑進行臨床開發
ASC30_48 FDC（GLP-1R/GIPR激動劑）2 mg/kg ASC30 和 5 mg/kg ASC48口服,
More news about: 歌禮製藥有限公司
Jul 14, 2026, 09:51 ET DEADLINE NEXT WEEK: Berger Montague Advises Veritone, Inc. (NASDAQ: VERI) Investors to Contact the Firm Before July 20, 2026
alleges Veritone and its senior executives overstated its revenue by inaccurately recording and misclassifying certain revenue and costs under ASC 606, while concealing deficient internal controls over financial reporting that would ultimately require a restatement of previously issued financial
More news about: Berger Montague
Jul 10, 2026, 08:00 ET Thomas Lemon Joins PKF O'Connor Davies as Partner in Commercial Tax Practice
specializing in complex tax consulting for private equity firms, partnerships, corporations and high-net-worth individuals. He brings deep experience in ASC 740, Subchapter K, partnership taxation, mergers and acquisitions, tax quality and risk management and business development."Tom's depth of experience
More news about: PKF O’Connor Davies
Jul 09, 2026, 13:14 ET SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 28, 2026 in Hub Group, Inc. Lawsuit - HUBG
stating that revenue was recognized "when we transfer services to our customers in an amount that reflects the consideration we expect to receive" under ASC Topic 606. Each filing also contained certifications from the CEO and CFO stating that disclosure controls and procedures were "effective" and that financial
More news about: SueWallSt.com
Jul 08, 2026, 07:00 ET RoosterBio and Applied StemCell Partner to Advance Scalable iPSC-Based Bioprocess Solutions
StemCellApplied StemCell, Inc. (ASC) is a biotechnology company specializing in genome engineering and induced pluripotent stem cell (iPSC) technologies. Leveraging its proprietary TARGATT™ targeted integration platform alongside advanced gene editing and iPSC engineering capabilities, ASC develops precise, scalable
More news about: RoosterBio, Inc.
Jul 07, 2026, 07:00 ET DragonGC Adds Precise Workflows for Securities Disclosure
disclosure language against market practice.Accounting Topic Comment Letter Trends: Analyzes SEC Staff comment letter trends for a selected ASC topic and benchmarks a draft filing against observed Staff concerns, enabling companies to anticipate and address potential comments before they are
More news about: DragonGC
Jul 05, 2026, 21:10 ET Ascletis Submits Two IND Applications to the U.S. FDA for the Treatment of Obesity: ASC36 Once-Monthly Injection, a Peptide Amylin Receptor Agonist, and ASC36_35 FDC Once-Monthly Injection, a Co-Formulation of ASC36 Plus Peptide GLP-1R/GIPR Agonist ASC35
GLP-1R/GIPR dual peptide agonist and ASC37, a GLP-1R/GIPR/GCGR triple peptide agonist, ASC39, an eloralintide-like potent and amylin-selective oral small molecule amylin receptor agonist, and ASC30_39 FDC, a fixed-dose combination (FDC) of ASC30 (GLP-1RA) and ASC39 (amylin RA), for chronic weight management.
More news about: Ascletis Pharma Inc.